February 8, 2012
| Bio-IT World > Short News & Analysis


Short News & Analysis



June 25, 2009 | Entelos Retains Seven Hills Partners
Entelos has posted a copy of its proxy statement and proxy card, in connection with resolutions to be voted on at the Entelos Annual Stockholder Meeting taking place on June 23, 2009. It also announced that, “following receipt of unsolicited expressions of interest from certain third parties investigating the possibility of acquiring or entering into another strategic transaction with Entelos, the Company has retained Seven Hills Partners LLC as its financial advisor. Seven Hills is assisting the Company’s Board of Directors and senior management in evaluating various strategic alternatives which the Company hopes will enhance shareholder value, including various financing and capital raising alternatives.” Read release.

Ingenuity and Integromics Integration For Genomics Analysis
Integromics and Ingenuity Systems announced the integration of RealTime StatMiner and Integromics Biomarker Discovery (IBD) for Tibco Spotfire with Ingenuity Pathway Analysis (IPA).  The resulting platform provides a uniform solution for researchers to visualize and statistically assess genomics data, and then identify relevant biological processes and pathways.

“Our main objective is to provide our joint customers with relevant workflows that help them best understand their gene expression data,” said Tuan Nguyen, VP, Partner and Professional Services, Ingenuity Systems. “We felt it was important to provide a streamlined way for researchers to move from raw data analysis to understanding relevant biology.” Read release.

BioSeek and Merck Serono Extend 2008 Agreement
BioSeek signed a new, three-year collaboration agreement with Merck KGaA, acting for its division Merck Serono, extending and expanding the companies’ previous 2008 compound profiling agreement. Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed. Read release.
--

This article first appeared in Bio-IT World’s Predictive Biomedicine newsletter. Click here for a free subscription.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .